Biobeat’s remote patient monitoring health-AI platform includes a wearable monitor which utilizes a photoplethysmography-based (PPG) sensor to continuously provide accurate patient readings of 13 health parameters, including cuffless blood pressure, pulse rate, respiratory rate, blood oxygen saturation, and more. Aggregated patient health data is viewed by medical staff via Biobeat’s secure cloud-based patient management platform, which utilizes a real-time early warning score system that incorporates advanced AI-based algorithms to provide alerts on patient health status and potential deterioration. Biobeat’s wearable devices are the first devices to be FDA-Cleared for cuffless non-invasive blood pressure monitoring and are also CE Mark certified.

Rimidi’s cardiometabolic platform supports disease management of some of the most prevalent and costly chronic conditions. The platform provides access to the tools required to manage multiple disease states – Diabetes, Cardiovascular Disease/Hypertension, Heart Failure, Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH), and Obesity. The platform consolidates relevant clinical data from the EMR for each disease state with patient-generated health data from connected devices or surveys, and layers clinical decision support that can be mapped against national or practice guidelines. Our cardiometabolic snapshot allows clinicians to quickly assess patient status for each comorbid disease state -- are screenings up to date? Are key metrics well-controlled?

Differing from traditional methods in that it is cuffless, Biobeat’s wireless, non-invasive, medical-grade chest-worn device enables blood pressure monitoring by automatically capturing critical patient health data throughout the day. Easy and intuitive to use and apply, it is designed to be set up at patients' homes or at the clinic, without the need for the presence of medical personnel. Since the patient is unaware of the measurements being taken with our optical sensor, this eliminates the "white coat" effect seen with cuff-based devices.

The Biobeat device is providing not only the blood pressure values, but also the Pulse Rate, Mean Arterial Pressure, Cardiac Output, and Systemic Vascular Resistance. This information will help the practitioner with clinical insights of the root cause of hypertension, as well as helping to better adjust medications, thus improving outcomes.

In the sales process, we often hear “Doesn’t Epic (or other EHR) do that?” Rimidi is not built to replace the EHR, but to enhance it by bringing in additional data sets, providing more efficient workflows, and improving the user experience. Rimidi can install and configure its platform within 3-6 weeks which is significantly faster and more cost effective than onsite EHR teams can build and support enhancements to meet clinical needs. Rimidi’s modern technology stack enables rapid cycle innovation and iteration post-go live.

Rimidi’s cardiometabolic platform is most often compared to other Remote Patient Monitoring solutions, but the platform-approach to RPM allows Rimidi to do so much more. Some key differentiators of the Rimidi platform are: (1) tight integration with leading EHRs via SMART on FHIR, (2) the breadth of the comorbid disease states we cover, (3) our incorporations of patient-reported outcomes and social determinants of health measures and (4) our Clinical Decision Support engine. Rimidi’s CDS cards support almost any insight or intervention a client wants: RPM data alerting and interventions, referral management, lab or medication recommendations, clinical trial identification, and more.